NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.
该合作包括在2025年第二季度开始的一项第1阶段临床研究。
The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.
新加坡国家皮肤中心、赛诺菲安万特和科学技术研究局（A*STAR）已签署谅解备忘录，以推动痤疮治疗研究。
The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.
合作包括涉及轻度痤疮患者的第1期临床研究，预计将于2025年第二季度开始。
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.
此外，将开展一项转化研究，以探索影响痤疮严重程度的关键生物标志物。
The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.
这种慢性炎症性皮肤状况影响着大部分人口，大约80%的青少年和数量不断增加的成年人（估计约40%）患有这种状况。
译文内容由第三方软件翻译。
